Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126814
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ribera, Josep Maria | - |
dc.contributor.author | Oriol, Albert | - |
dc.contributor.author | González, Marcos | - |
dc.contributor.author | Vidriales, Belén | - |
dc.contributor.author | Brunet, Salut | - |
dc.contributor.author | Esteve, Jordi | - |
dc.contributor.author | Potro, Eloy del | - |
dc.contributor.author | Rivas, Concepción | - |
dc.contributor.author | Moreno, Maria José | - |
dc.contributor.author | Tormo, Mar | - |
dc.contributor.author | Martín Reina, Victoria | - |
dc.contributor.author | Sarrá, Josep | - |
dc.contributor.author | Parody, Ricardo | - |
dc.contributor.author | Pérez de Oteyza, Jaime | - |
dc.contributor.author | Bureo, Encarna | - |
dc.contributor.author | Bernal, Maria Teresa | - |
dc.contributor.author | Programa Español de Tratamiento en Hematología (PETHEMA) | - |
dc.contributor.author | Grupo Español de Trasplante Hemopoyético (GETH) | - |
dc.date.accessioned | 2018-12-10T09:39:47Z | - |
dc.date.available | 2018-12-10T09:39:47Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/126814 | - |
dc.description.abstract | Background: Imatinib, given concurrently or alternating with chemotherapy, has improved the response and survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) but relapses are still frequent. The aim of this study was to evaluate the feasibility and results of giving imatinib concurrently with intensive chemotherapy, stem cell transplantation and post-transplant imatinib maintenance therapy in patients with newly diagnosed Ph(+) ALL. Design and Methods: This was a phase II study of patients with newly diagnosed Ph(+) ALL given standard chemotherapy, together with imatinib (400 mg/day) until stem cell transplantation, followed by imatinib maintenance therapy for all patients regardless of the molecular status of the disease. Results: Of the 30 patients included, 27 (90%) achieved complete remission, one was resistant to treatment and two died during induction therapy. The percentages of major and complete molecular responses were 86% and 21% after induction, and 81% and 65% after consolidation, respectively. Similar results were observed assessing minimal residual disease by Sow cytometry. Of the 27 patients who achieved complete remission, 21 underwent stem cell transplantation (16 allogeneic, 5 autologous). Imatinib (400 mg/day) could be administered after transplantation for a median of 3.9 months in 12 patients, although it was interrupted in 10 patients (in 2 cases because of side effects of the drug). Nine patients relapsed, four before and five after stem cell transplantation and eight patients died of transplant-related causes. With a median follow-up of 4.1 years, the probabilities (95% CI) of disease-free and overall survival were 30% (15% to 45%) and 30% (16% to 45%), respectively. Conclusions: These results confirm that imatinib is an effective first-line treatment for adult Ph(+) ALL when given concurrently with chemotherapy, making stem cell transplantation feasible in a high proportion of patients. However, post-transplantation imatinib administration was limited, mainly because of transplantation-derived complications rather than drug-specific toxicity. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Ferrata Storti Foundation | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2009.011221 | - |
dc.relation.ispartof | Haematologica, 2010, vol. 95, num. 1, p. 87-95 | - |
dc.relation.uri | https://doi.org/10.3324/haematol.2009.011221 | - |
dc.rights | (c) Ferrata Storti Foundation, 2010 | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Leucèmia | - |
dc.subject.classification | Quimioteràpia | - |
dc.subject.other | Leukemia | - |
dc.subject.other | Chemotherapy | - |
dc.title | Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2018-07-24T13:05:35Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 19797728 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
RiberaJM.pdf | 236.29 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.